Compounds of formula (II) where R 1 is in the para or meta position and is (A); R 2 and R 3 are each independently selected from hydrogen, nitro, C 1-6 alkyl, C 3-6 cycloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-4 alkoxyl, C 1-6 alkylamino, C 1-6 dialkylamino, C 1-6 akylC 1-4 alkoxyl, C 1-6 alkylaminoC 1-6 alkyl, amino, cyano, halogeno, trifluoromethyl, ?CO 2 R 12 and ?CONR 12 R 13 , where R 12 and R 13 are independently selected from hydrogen or C 1-6 alkyl, or R 2 and R 3 together with the phenyl to which they are attached form a 9 or 10 membered bicyclic ring system; R 4 is C 1-4 alkyl; R 5 is selected from hydrogen and C 1-4 alkyl; R 6 is selected from C 1-6 alkyl, C 1-4 alkyl(C 4-6 )cycloalkyl, C 1-6 alkyl(C 1-6 )alkoxyl, C 1-6 alkylS(C 1-6 )alkyl, C 1-4 alkylsulphonyl(C 1-4 )alkyl; (B) where q is an integer from 1 to 6 and R 14 is halogeno; R 7 is selected from C 1-6 alkyl, C 1-8 alkoxylcarbonyl, C 2-6 alkenyl, 1,3-benzodioxol-5-yl and aryl each optionally substituted by one or more substituents selected from C 1-4 alkoxy, C 1-6 alkyl, cyano, halogeno, and trifluoromethyl; R 8 is aryl, heteroaryl, a bicyclic heteroaryl ring system linked to the nitrogen via a ring carbon or a 9 or 10 membered bicyclic ring system linked to the nitrogen via a ring carbon and each ring is optionally substituted with up to two substituents, which may be the same or different, and are selected from C 1-6 alkyl, C 1-4 alkoxy, C 1-4 alkylthio, C 1-6 alkylC 1-4 alkoxyl, C 1-6 alkylaminoC 1-6 alkyl, hydroxy, ?CO 2 H, ?(CH 2 ) p OH where p is 1 or 2, cyano, halogeno, and trifluoromethyl; R 9 and R 10 are each independently selected from hydrogen and C 1-4 alkyl or R 8 and R 9 together with the nitrogen to which they are attached form a dihydroindolyl, or a dihidroquinolinyl group; R 11 is selected from carboxyl, tetrazolyl, alkyl sulphonylcarbamyl, sulfo and sulfino; Y is oxygen, sulphur or sulfonyl; m is 0 or 1; and n is 0 or an integer from 1 to 4 with the proviso that when m and n cannot both be 0 and when m is 1, n is 0; or a pharmaceutically acceptable salt or in vivo hydrolyzable ester thereof. The compounds inhibit the interaction of vascular cell-adhesion molecule-1 and fibronectin with integrin very late antigen 4 (a 4 b 1 ). They have therapeutic applications such as in multiple sclerosis, rheumatoid arthritis, asthma, coronary artery disease and psoriasis